Overall prevalence proportions for DMO and CSDMO observed in the 27 178 screened patients in the DRSSW dataset
| Case label | Description | Prevalence (%) | ‘Exact’ binomial 95% CI |
| DMO | DMO (any severity) in one or both eyes | 7.05 | 6.75 to 7.37 |
| In one eye only | 4.72 | 4.47 to 4.98 | |
| In both eyes | 2.33 | 2.15 to 2.52 | |
| CSDMO-SL | Sight loss (CVA <6/6) attributable to DMO, in at least one eye. | 2.75 | 2.56 to 2.95 |
| CSDMO-VI | CVA <6/6 to >6/60 attributable to DMO, in at least one eye. | 2.64 | 2.45 to 2.84 |
| CSDMO-BL | CVA ≤6/60 in both eyes, one or both attributable to DMO. | 0.109 | 0.073 to 0.157 |
| CSDMO-PS | CVA <6/19 to >6/60 in the better seeing eye, the impairment attributable to DMO in one or both eyes. | 0.226 | 0.172 to 0.291 |
BL, blindness; CSDMO, clinically significant diabetic macular oedema; CVA, corrected visual acuity; DMO, diabetic macular oedema; DRSSW, Diabetic Retinopathy Screening Service for Wales; PS, partial sight; SL, sight loss; VI, visual impairment.